Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 2
2007 5
2008 4
2009 2
2010 3
2011 1
2012 1
2013 2
2014 2
2015 1
2016 10
2017 3
2018 13
2019 12
2020 28
2021 30
2022 18
2023 25
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Kang YK, et al. Among authors: zhou y. J Clin Oncol. 2021 Oct 1;39(28):3128-3139. doi: 10.1200/JCO.21.00217. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343033 Free PMC article. Clinical Trial.
Spin-torque-driven antiferromagnetic resonance.
Zhou Y, Guo T, Han L, Liao L, He W, Wan C, Chen C, Wang Q, Qiao L, Bai H, Zhu W, Zhang Y, Chen R, Han X, Pan F, Song C. Zhou Y, et al. Sci Adv. 2024 Jan 12;10(2):eadk7935. doi: 10.1126/sciadv.adk7935. Epub 2024 Jan 12. Sci Adv. 2024. PMID: 38215195 Free PMC article.
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. Nan Y, et al. Among authors: zhou y. J Hepatol. 2021 Aug;75(2):454-461. doi: 10.1016/j.jhep.2021.05.003. Epub 2021 May 19. J Hepatol. 2021. PMID: 34019941
Antiferromagnetic Inverse Spin Hall Effect.
Huang L, Zhou Y, Qiu H, Bai H, Chen C, Yu W, Liao L, Guo T, Pan F, Jin B, Song C. Huang L, et al. Among authors: zhou y. Adv Mater. 2022 Oct;34(42):e2205988. doi: 10.1002/adma.202205988. Epub 2022 Sep 19. Adv Mater. 2022. PMID: 36055979
The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.
Zhuang Q, Liao A, He Q, Liu C, Zheng C, Li X, Liu Y, Wang B, Liu S, Zhang Y, Lin R, Chen H, Deng M, Tang Y, He C, Dai W, Tang H, Gong L, Li L, Xu B, Yang C, Zhou B, Su D, Guo Q, Li B, Zhou Y, Wang X, Fei S, Wu H, Wei S, Peng Z, Wang J, Li Y, Wang H, Deng T, Ding S, Li F, Chen M, Xiao Y. Zhuang Q, et al. Among authors: zhou y. J Gastroenterol Hepatol. 2024 Apr;39(4):658-666. doi: 10.1111/jgh.16471. Epub 2024 Jan 22. J Gastroenterol Hepatol. 2024. PMID: 38251791 Clinical Trial.
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
Li J, Zhang J, Zhang Y, Qiu H, Zhou Y, Zhou Y, Zhang X, Zhou Y, Zhu Y, Li Y, Wang M, Shen K, Tao K, Wu X, Wang H, Zhang B, Ling J, Ye Y, Wu X, Qu H, Ma Y, Jiao X, Zheng H, Jin J, Liu Z, Tan M, Fang Y, Zhang P, Zhang N, Lei C, Cai Z, Liang B, Peng Z, Huang Z, Dong J, Shen L. Li J, et al. Among authors: zhou y. Eur J Cancer. 2024 Jan;196:113439. doi: 10.1016/j.ejca.2023.113439. Epub 2023 Nov 14. Eur J Cancer. 2024. PMID: 37980854 Clinical Trial.
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
Heinrich MC, Zhang X, Jones RL, George S, Serrano C, Deng Y, Bauer S, Cai S, Wu X, Zhou Y, Tao K, Zheng Z, Zhang J, Cui Y, Cao H, Wang M, Hu J, Yang J, Li J, Shen L. Heinrich MC, et al. Among authors: zhou y. Clin Cancer Res. 2024 Feb 16;30(4):719-728. doi: 10.1158/1078-0432.CCR-23-1861. Clin Cancer Res. 2024. PMID: 38032349 Clinical Trial.
162 results